Genetic Susceptibility to Bladder Cancer

M.D. Anderson Cancer Center

Status: Active, not recruiting

Conditions: Bladder Cancer

Treatments: Behavioral: Interviews

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT00848289

LAB98-040 (Other Identifier)

5R01CA074880 (U.S. NIH Grant/Contract)

5P50CA091846-14 (U.S. NIH Grant/Contract)

H-8577 (Other Identifier)

NCI-2021-06405 (Other Identifier)

Details and patient eligibility

About

This clinical research study will identify biologic and lifestyle factors which increase a person's risk of developing specific cancer. Researchers propose to conduct a case-control study examining interindividual differences in susceptibility to tobacco carcinogenesis as predictors of bladder cancer risk. We will measure susceptibility to tobacco carcinogenesis and this will include studies of the genetic modulation of carcinogen activation and detoxification and of chromosome sensitivity to tobacco mutagens.

Full description

Researchers propose to conduct a case-control study examining interindividual differences in susceptibility to tobacco carcinogenesis as predictors of bladder cancer risk. We will measure susceptibility to tobacco carcinogenesis and this will include studies of the genetic modulation of carcinogen activation and detoxification and of chromosome sensitivity to tobacco mutagens.

Enrollment: 6,086 patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Subject has a histologically confirmed diagnosis of superficial or muscle-invasive bladder cancer
• Subject is a Texas resident.
• Subject can understand English or a qualified translator is available for the interview.
• Subjects of any age, gender, or ethnicity are eligible to participate in the study.
• Subject consents to participate in the study.

Exclusion criteria

• Subject has had prior treatment with systemic chemotherapy or radiotherapy in the past 6 months.
• Subject has been diagnosed with superficial or muscle-invasive bladder cancer more than twelve months ago.

Trial design

6,086 participants in 1 patient group

Participants with Bladder Cancer

Description:

Patients diagnosed with superficial or muscle-invasive bladder cancer. Specimens, personal and follow-up telephone interviews will be collected and conducted.

Treatment:

Behavioral: Interviews